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Abstract Noonan syndrome (NS) is an autosomal dominant disorder characterized by short stature, typical
craniofacial dysmorphism, skeletal anomalies, congenital heart defects, and predisposition to ma-
lignant tumors. In approximately 50% of cases, the disease is caused by missense mutations in
the PTPN11 gene. To date, solid tumors, and particularly brain tumors and rhabdomyosarcomas,
have been documented in patients with NS; however, few cases of neuroblastoma associated with
NS have been reported. Here we report an unusual case of neuroblastoma with mediastinal, retro-
peritoneal, and medullar locations associated in a NS patient carrying a PTPN11 germline missense
mutation (p.G60A). This missense mutation occurs within the N-SH2 domain of the PTPN11 gene
and has been reported to be associated with acute leukemia in NS patients. The association of this
p.G60A PTPN11 mutation with neuroblastoma provides new evidence that gain of function
PTPN11 mutations may play an important role in the pathogenesis of solid tumors associated with
Noonan syndrome.  2008 Elsevier Inc. All rights reserved.1. Introduction
Noonan syndrome (NS; MIM #163950) is an autosomal
dominant disorder characterized mainly by short stature,
hypertelorism, downward eye slant, low-set posteriorly ro-
tated ears, epicanthic folds, wide-spaced nipples, and short
neck with webbing or redundancy of skin. Other typical
features include a characteristic chest deformity with a pec-
tus carinatum and pectus excavatum, mild mental retarda-
tion, predisposition to malignant tumors, and congenital
cardiac anomalies [1,2].
In ~50% of cases, NS is caused by missense mutations in
the PTPN11 gene (protein-tyrosine phosphatase, nonreceptor-
type 11), coding for SHP-2. The SHP-2 gene product is
a nonreceptor protein tyrosine phosphatase containing two
SH2 domains (N-SH2, C-SH2), a PTP domain, and a C-tail
with tyrosine phosphorylation sites and a proline-rich motif
[3]. SHP-2 participates in signal transduction downstream
of growth factor receptors to regulate multiple cellular
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doi:10.1016/j.cancergencyto.2007.12.005responses, including proliferation, differentiation, and mi-
gration [4].
SHP-2 is the first known tyrosine phosphatase that func-
tions as an oncogene in human cancer [5]. Indeed, germline
and somatic mutations are reported to enhance the function
of SHP-2. For instance, N-SH2 mutations disrupt inactivat-
ing interactions with the PTP domain and upregulate phos-
phatase activity, causing an inappropriate activation of the
RAS/MAPK cascade (RAS-mitogen activated protein ki-
nase). Commonly, germline mutations in SH2/PTP are ob-
served in NS patients, whereas somatic mutations are often
identified in hematological myeloid malignancies, includ-
ing juvenile myelomonocytic leukemia, myelodysplastic
syndromes, acute lymphoblastic leukemia, and acute mye-
loid leukemia [6]. Both myeloid leukemias and a variety of
solid tumors including astrocytoma, glioblastoma, glioma,
medulloblastoma, rhabdomyosarcoma, melanoma, lung ad-
enocarcinoma, breast and colon cancers have been de-
scribed in patients with NS [7e9]. To date, few cases of
neuroblastic tumors have been reported in NS patients
[10e12].
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in a patient with a NS phenotype, a patient in whom mul-
tiple neuroblastic tumors were detected.
2. Materials and methods
2.1. Case report
The propositus was the second child of unrelated white
parents. She was born at 39 weeks gestation with a birth
weight of 2,725 g (10th to 25th percentile), length of 48
cm (25th percentile), and occipitofrontal circumference of
34 cm (50th to 90th percentile). The results of antenatal fe-
tal ultrasound were not significant, apart from neck translu-
cency (crownerump length of 95 mm) and agenesis of the
venosus ductus. At birth, she presented a severe respiratory
distress due to inhalation of meconium, and had decreased
tone and feeding difficulties. She remained 2 days in the
neonatal intensive care unit.
During this time, a heart murmur was noted and X-radiog-
raphy of the chest revealed a cardiomegaly (cardiothoracic
index of 0.67). Echocardiography revealed a ventricular sep-
tal defect, a secundum atrial septal defect with left-to-right
shunting, and moderate pulmonary stenosis without evidence
of dysplastic pulmonary valve. Abdominal echography
revealed a hepatic steatosis. Clinically, she presented an ex-
cessive nuchal skin (cystic hygroma), hypertelorism, micro-
cephaly, small nasal bridge, long smooth philtrum, webbing
of the neck, wide-spaced nipples, and the persistence of
a large anterior fontanelle. A systolic murmur was best heard
in the upper left sternal border. NS diagnosis was suspected
and mutational analysis of PTPN11 gene was carried out.
At 5 months of age, a computed tomography scan and
radiographic examinations of the chest and abdomen re-
vealed several posterior mediastinal and retroperitoneal
masses with calcifications. The diagnosis of neuroblastoma
was confirmed by scintigraphy with meta-iodobenzylguani-
dine, dosage of tumor markers, and histological analysis.
Further tests revealed bone marrow infiltration and cranial
metastases. The MYCN gene was not amplified. Urinary
catecholamine metabolites analysis showed increased va-
nillylmandelic acid and homovanillic acid values (273.8
and 285.08 mg/mg creatinine, respectively). The patient re-
ceived chemotherapy treatment including four cycles of
carboplatin and VP16 followed by three cycles of hydroxy-
urea, cyclophosphamide and doxorubicin (SIOP Europe
Neuroblastoma 99.03 protocol). The patient achieved com-
plete remission.
2.2. Mutation analysis of the PTPN11 gene
Patient genomic DNA sample was extracted from pe-
ripheral lymphocytes using a Qiagen kit (Qiagen, Valencia,
CA; Courtaboeuf, France). The PTPN11 mutational analy-
sis on the genomic DNA sample was performed on exons 2,
3, 4, 7, 8, 12, and 13 and their flanking intronic boundaries,because these coding regions encompass the mutational hot
spot sites [13].
The PCR reactions were performed as previously de-
scribed [14]. PCR products were analyzed by denaturing
high-performance liquid chromatography (DHPLC), using
a WAVE HPLC and DNASep column (Transgenomic, Elan-
court, France) as previously described [15]. The abnormal
DHPLC profiles were directly sequenced bidirectionally us-
ing an ABI 3100 capillary array sequencer (Applied Bio-
systems, Foster City, CA).
3. Results and discussion
Most commonly, NS is associated with a variety of
pediatric hematologic malignancies, including juvenile
myelomonocytic, lymphoblastic, and acute myelogenous
leukemias [16,17]. Moreover, solid tumors (including brain
and thyroid tumors, rhabdomyosarcoma, cutaneous mela-
noma, and colon cancer) are frequent in NS patients.
There have been few reported cases of neuroblastoma in
association with NS, and all of these neuroblastic tumors
were mediastinal masses [10e12]. In the present case, how-
ever, the neuroblastic tumors were located in both medias-
tinal and retroperitoneal sites and also showed medullary
and cranial dissemination. Neuroblastoma is a malignant
childhood tumor of neuroectodermal cells derived from
neural crest and migrating to the adrenal medulla and the
sympathetic nervous system [18].
About half of the NS patients have germline missense
mutations in the PTPN11 gene [19]. The PTPN11 gene, lo-
cated in 12q24.1 (MIM 163950; http://www.ncbi.nlm.nih.
gov/sites/entrez?db5omim), encodes the SHP-2 protein.
This protein is a member of a subfamily of cytoplasmic
Src homology-2 (SHP-2) domain-containing protein tyro-
sine phosphatases (PTPs), which play an important role in
several intracellular signal transduction pathways and con-
trol a number of developmental processes, including car-
diac semilunar valvulogenesis [3]. Mutations in tyrosine
kinase or phosphatase can result in malignant transforma-
tion by intracellular accumulation of tyrosine-phosphory-
lated proteins [20]. However, gain-of-function mutations
in PTP including SHP-2 have recently been associated with
tumorigenesis.
In the present case, the PTPN11 mutational analysis per-
formed on genomic DNA of the proband, identified a het-
erozygous transition G/C at position 179 within exon 3,
predicting the substitution of glycine by an alanine residue
(p.Gly60Ala) within the N-SH2 domain of the PTPN11
gene. Most of the PTPN11 mutations are recurrent and
cluster in the N-SH2 (exon 3) and PTP-domains (exons 7,
8, and 13) [17,21]. The PTPN11 mutations identified in pa-
tients with NS destabilize the catalytically inactive confor-
mation and activate the SHP-2 protein. In addition, almost
all of the mutations occurring within exon 3 of PTPN11
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acids that interact with the PTPase domain [19].
The missense mutation p.G60A identified in the N-SH2
domain of the PTPN11 gene has been reported in 4% of
cases to be associated with acute myeloid leukemia and
acute lymphoblastic leukemia in NS patients [6,22]. Previ-
ous data suggest that low levels of SHP2 activation result
in NS, whereas higher levels of activity may be required
for leukemogenesis [5]. Indeed, SHP2 mutants promote
myeloid cell survival and proliferation, and preferentially
enhance monocytoid differentiation [23].
Recently, Bentires-Alj et al. [7] reported a series of solid
tumors associated with somatic PTPN11 mutations. Among
them, the vast majority were located within the N-SH2 at
the N-SH2/PTP interface, and all of these mutations con-
tribute to oncogenesis by increased basal PTP activity. In
89 patients with neuroblastomic tumors, the authors identi-
fied only three PTPN11 mutations: the missense p.Y62C
(exon 3), p.E69K (exon 3), and p.T507K (exon 13) muta-
tions. Two of these were somatic mutations, but one
(p.Y62C) was germline, suggesting an undiagnosed, and
thus probably mild, NS in that patient [7].
The present findings suggest that the PTPN11 mutations,
thought to be implicated in leukemogenesis by gain of
function in SHP-2 and in inappropriate activation of SHP-
2, may play an important role in the pathogenesis of solid
tumors associated with NS. To our knowledge, the present
patient is the only one in whom a germline PTPN11
c.G179OC (p.G60A) missense mutation affecting exon 3
has been reported to be associated with neuroblastoma.
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